ESRP2 抗体 (C-Term)
-
- 抗原 See all ESRP2 抗体
- ESRP2 (Epithelial Splicing Regulatory Protein 2 (ESRP2))
-
抗原表位
- C-Term
-
适用
- 人, 小鼠
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This ESRP2 antibody is un-conjugated
-
应用范围
- Western Blotting (WB)
- 交叉反应
- 小鼠
- 纯化方法
- Purified
- 免疫原
- Esrp2 antibody was raised in rabbit using the C terminal of Esrp2 as the immunogen
- Top Product
- Discover our top product ESRP2 Primary Antibody
-
-
- 应用备注
- Optimal conditions should be determined by the investigator.
- 说明
-
Esrp2 Blocking Peptide, catalog no. 33R-5174, is also available for use as a blocking control in assays to test for specificity of this Esrp2 antibody
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 浓度
- Lot specific
- 缓冲液
- Lyophilized powder. Add 50 µL of distilled water. Final antibody concentration is 1 mg/mL in PBS buffer.
- 注意事项
- Avoid repeated freeze/thaw cycles.
- 储存条件
- 4 °C/-20 °C
- 储存方法
- Store at 4 °C, following reconstitution, aliquot and store at -20 °C.
-
- 抗原
- ESRP2 (Epithelial Splicing Regulatory Protein 2 (ESRP2))
- 别名
- Esrp2 (ESRP2 产品)
- 别名
- RBM35B antibody, 9530027K23Rik antibody, Rbm35b antibody, RGD1310855 antibody, cb404 antibody, fa07a06 antibody, rbm35b antibody, sb:cb404 antibody, zgc:77254 antibody, epithelial splicing regulatory protein 2 antibody, microRNA 6773 antibody, ESRP2 antibody, Esrp2 antibody, MIR6773 antibody, esrp2 antibody
- 背景
- Esrp2 is an mRNA splicing factor that regulates the formation of epithelial cell-specific isoforms. It specifically regulates the expression of FGFR2-IIIb, an epithelial cell-specific isoform of FGFR2. It also regulates the splicing of CD44, CTNND1, ENAH, 3 transcripts that undergo changes in splicing during the epithelial-to-mesenchymal transition (EMT). It acts by directly binding specific sequences in mRNAs and binds the GU-rich sequence motifs in the ISE/ISS-3, a cis-element regulatory region present in the mRNA of FGFR2. Synonyms: Polyclonal Esrp2 antibody, Anti-Esrp2 antibody, epithelial splicing regulatory protein 2 antibody, 9530027K23Rik antibody, Rbm35b antibody.
-